Elisabetta Patorno

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, United States

Boehringer Ingelheim (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)

Presentation(s):

• Contemporary Trends in the Utilization of Second-line Pharmacological Therapies for Type 2 Diabetes in the United States

  Friday, August 26, 2022
  5:30 PM – 5:45 PM CEST

• Trends and Prescription Patterns of Medications for Secondary Stroke Prevention in Denmark, 2013—2018

  Friday, August 26, 2022
  6:15 PM – 6:30 PM CEST

• Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

  Friday, August 26, 2022
  6:15 PM – 6:20 PM CEST

• Emulating Stratified Randomized Trials by Propensity Score Methods

  Saturday, August 27, 2022
  9:15 AM – 9:30 AM CEST

• Sodium-glucose Co-transporter 2 Inhibitors and the Risk of Early Bladder Cancer Events

  Saturday, August 27, 2022
  2:00 PM – 2:15 PM CEST

• Cardiovascular Outcomes in Patients with Type 2 Diabetes Who Added Either GLP1 Receptor Agonists or DPP4 Inhibitors to SGLT2 Inhibitor Therapy

  Sunday, August 28, 2022
  8:45 AM – 9:00 AM CEST

• Cardiovascular Effectiveness of Sodium—glucose Cotransporter 2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RA) in Routine Care of Frail People with Type 2 Diabetes

  Sunday, August 28, 2022
  9:00 AM – 9:15 AM CEST

• Cardiovascular Effectiveness of SGLT2 Inhibitors: Head-to-head Comparisons

  Sunday, August 28, 2022
  9:15 AM – 9:30 AM CEST

• Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-like peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

  Sunday, August 28, 2022
  9:30 AM – 9:45 AM CEST

• The Comparative Safety of Individual SGLT2 Inhibitors and the Risk of Diabetic Ketoacidosis

  Sunday, August 28, 2022
  2:00 PM – 2:15 PM CEST

• Risk of Hypoglycemia with Sodium Glucose cotransporter-2 Inhibitors vs. Alternative Glucose Lowering Medications in Patients with and Without Baseline Use of Insulin or Sulfonylurea

  Sunday, August 28, 2022
  2:30 PM – 2:45 PM CEST